About PLx Pharma (NASDAQ:PLXP)
PLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing nonsteroidal anti-inflammatory drugs and other pharmaceutical agents. Its lead product is Aspertec 325 mg, a novel formulation of aspirin that uses the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. The company's product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard delivery system, including PL1200 Ibuprofen 200 mg, a clinical-stage GI-safer ibuprofen product for pain and inflammation; and Aspertec 81 mg, a novel formulation of aspirin, which is in late-stage development. The company was founded in 2002 and is headquartered in Houston, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-2.18
Forward P/E Ratio-2.49
Sales & Book Value
Price / Sales47.57
Price / CashN/A
Book Value$0.53 per share
Price / Book8.02
EPS (Most Recent Fiscal Year)($1.95)
Return on Equity-143.33%
Return on Assets-48.40%
PLx Pharma (NASDAQ:PLXP) Frequently Asked Questions
What is PLx Pharma's stock symbol?
PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."
How were PLx Pharma's earnings last quarter?
PLx Pharma Inc (NASDAQ:PLXP) released its quarterly earnings results on Friday, May, 11th. The biotechnology company reported ($0.40) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.45) by $0.05. The biotechnology company had revenue of $81.46 million for the quarter. PLx Pharma had a negative return on equity of 143.33% and a negative net margin of 10.87%. View PLx Pharma's Earnings History.
What price target have analysts set for PLXP?
3 brokerages have issued 12-month price targets for PLx Pharma's shares. Their forecasts range from $12.00 to $14.00. On average, they anticipate PLx Pharma's share price to reach $13.00 in the next year. View Analyst Ratings for PLx Pharma.
Who are some of PLx Pharma's key competitors?
Some companies that are related to PLx Pharma include Chembio Diagnostics (CEMI), Emisphere Technologies (EMIS), Bellerophon Therapeutics (BLPH), Molecular Templates (MTEM), Acer Therapeutics (ACER), Intec Pharma (NTEC), Otonomy (OTIC), BioXcel Therapeutics (BTAI), Adamis Pharmaceuticals (ADMP), Affimed (AFMD), Leap Therapeutics (LPTX), Forward Pharma A/S (FWP), Motif (MTFB), Processa Pharmaceuticals (PCSA) and Merrimack Pharmaceuticals (MACK).
Who are PLx Pharma's key executives?
PLx Pharma's management team includes the folowing people:
- Mr. Michael J. Valentino, Exec. Chairman (Age 64)
- Ms. Natasha Giordano, Chief Exec. Officer, Pres and Director (Age 58)
- Mr. Gary L. Mossman, Sr. Advisor (Age 77)
- Mr. Ronald R. Zimmerman, Founder and Sr. Advisor (Age 65)
- Ms. Rita M. O'Connor CPA, Chief Financial Officer (Age 50)
When did PLx Pharma IPO?
(PLXP) raised $68 million in an initial public offering (IPO) on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James acted as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.
Has PLx Pharma been receiving favorable news coverage?
News stories about PLXP stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. PLx Pharma earned a daily sentiment score of 0.20 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 45.05 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are PLx Pharma's major shareholders?
PLx Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Texas Treasury Safekeeping Trust Co. (0.67%) and CVI Holdings LLC (0.53%). Company insiders that own PLx Pharma stock include David Emerson Jorden, Gary L Mossman and Michael J Valentino. View Institutional Ownership Trends for PLx Pharma.
Which major investors are buying PLx Pharma stock?
PLXP stock was purchased by a variety of institutional investors in the last quarter, including Texas Treasury Safekeeping Trust Co. and CVI Holdings LLC. Company insiders that have bought PLx Pharma stock in the last two years include David Emerson Jorden, Gary L Mossman and Michael J Valentino. View Insider Buying and Selling for PLx Pharma.
How do I buy shares of PLx Pharma?
Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PLx Pharma's stock price today?
One share of PLXP stock can currently be purchased for approximately $4.25.
How big of a company is PLx Pharma?
PLx Pharma has a market capitalization of $37.09 million and generates $780,000.00 in revenue each year. The biotechnology company earns $-15,340,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. PLx Pharma employs 14 workers across the globe.
How can I contact PLx Pharma?
PLx Pharma's mailing address is 8285 EL RIO STREET SUITE 130, HOUSTON TX, 77054. The biotechnology company can be reached via phone at 713-842-1249 or via email at [email protected]
MarketBeat Community Rating for PLx Pharma (PLXP)MarketBeat's community ratings are surveys of what our community members think about PLx Pharma and other stocks. Vote "Outperform" if you believe PLXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLXP will underperform the S&P 500 over the long term. You may vote once every thirty days.